Clinical Trial Update: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 study of TT-00420 (Tinengotinib) in metastatic cholangiocarcinoma patients who failed or relapsed after chemotherapy and FGFR inhibitor is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• TT-00420 (Tinengotinib) (Tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Cholangiocarcinoma Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING